東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The role of organic cation transport...

Chen, Eugene Chia-Te.

FindBook

Google Book

Amazon

博客來

The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin./
作者:	Chen, Eugene Chia-Te.
面頁冊數:	168 p.
附註:	Source: Dissertation Abstracts International, Volume: 76-06(E), Section: B.
Contained By:	Dissertation Abstracts International76-06B(E).
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3681185
ISBN:	9781321538205

The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin.
Chen, Eugene Chia-Te.

The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin. - 168 p.

Source: Dissertation Abstracts International, Volume: 76-06(E), Section: B.

Thesis (Ph.D.)--University of California, San Francisco, 2015.

Metformin, the most widely prescribed anti-diabetic drug, requires transporters to enter tissues involved in its pharmacologic action, including liver, kidney and peripheral tissues. Although membrane transporters responsible for the liver and kidney uptake of metformin have been identified, the mechanism in which metformin enters peripheral tissues is not completely understood. Organic cation transporter 3 (OCT3, SLC22A3) transports metformin in vitro and is expressed ubiquitously. The goals of this research are to determine the role of OCT3 in metformin disposition and response, identify OCT3 inhibitors that could potentially result in clinical drug-drug interactions when co-administered with metformin, and develop a method to predict competitive and non-competitive inhibitors of transporters.

ISBN: 9781321538205Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin.
LDR:03636nmm a2200301 4500 001 2066876
005 20160205084508.5
008 170521s2015 ||||||||||||||||| ||eng d
020 $a 9781321538205
035 $a (MiAaPQ)AAI3681185
035 $a AAI3681185
040 $a MiAaPQ $c MiAaPQ
100 1 $a Chen, Eugene Chia-Te. $3 3181729
245 1 4 $a The role of organic cation transporters in the pharmacokinetics and pharmacodynamics of metformin.
300 $a 168 p.
500 $a Source: Dissertation Abstracts International, Volume: 76-06(E), Section: B.
500 $a Adviser: Kathleen M. Giacomini.
502 $a Thesis (Ph.D.)--University of California, San Francisco, 2015.
520 $a Metformin, the most widely prescribed anti-diabetic drug, requires transporters to enter tissues involved in its pharmacologic action, including liver, kidney and peripheral tissues. Although membrane transporters responsible for the liver and kidney uptake of metformin have been identified, the mechanism in which metformin enters peripheral tissues is not completely understood. Organic cation transporter 3 (OCT3, SLC22A3) transports metformin in vitro and is expressed ubiquitously. The goals of this research are to determine the role of OCT3 in metformin disposition and response, identify OCT3 inhibitors that could potentially result in clinical drug-drug interactions when co-administered with metformin, and develop a method to predict competitive and non-competitive inhibitors of transporters.
520 $a In this dissertation, we showed that ablation of Oct3 in mice results in dramatic changes in the pharmacokinetics of metformin. In particular, the apparent volume of distribution, clearance and bioavailability of metformin were decreased in Oct3 knockout mice. We also showed that Oct3 knockout mice had reduced response to metformin. Notably, the effect of metformin on glucose tolerance is reduced in mice lacking Oct3, and that a likely explanation for this is reduced metformin accumulation in peripheral sites such as adipose tissue. Analysis of data from healthy volunteers receiving metformin revealed that a reduced function OCT3 genetic variant associated with attenuated response to metformin. In addition, we developed and conducted a high-throughput screen (HTS) against a large library of 2,556 prescription drugs and bioactive compounds for OCT3 inhibitors. We identified 210 potent OCT3 inhibitors, 23 of which could potentially cause drug-drug interactions with metformin. In order to enhance our currently limited understanding of inhibitor-transporter interactions, we developed a methodology combining structure-based and cell-based HTS to rapidly identify competitive and non-competitive inhibitors of OCT1, a paralog of OCT3, which plays a critical role in metformin disposition and response. Our method has broad implications for using combined in silico and HTS methods to not only identify ligands of transporters, but to understand their mechanisms of interaction with transporters.
520 $a Our findings have important implications for understanding metformin disposition and pharmacologic response, and pave the way for future studies of OCT3-mediated drug-drug interactions. Additionally, the combined modeling and HTS methodology we developed can accelerate transporter inhibition studies that are mandated by regulatory agencies during drug development.
590 $a School code: 0034.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Pharmacology. $3 634543
690 $a 0572
690 $a 0419
710 2 $a University of California, San Francisco. $b Pharmaceutical Sciences and Pharmacogenomics. $3 1023490
773 0 $t Dissertation Abstracts International $g 76-06B(E).
790 $a 0034
791 $a Ph.D.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3681185